Key result
The in vitro contracture test for malignant hyperthermia susceptibility showed a diagnostic sensitivity of 99.0% (95% CI 94.8-100.0%) and a specificity of 93.6% (95% CI 89.2-96.5%).
Why the study?
Does the in vitro contracture test (IVCT) accurately diagnose malignant hyperthermia susceptibility in patients with previous fulminant MH compared to low-risk subjects?
Population
105 patients with previous fulminant malignant hyperthermia and 202 normal, low-risk subjects without family…
Comparison
In vitro contracture test according to the… vs Low-risk subjects (controls)
Design
Cross-sectional
Authors
Loading...
IVCT achieves high sensitivity with satisfactory specificity for MH; confirms EMHG protocol utility but leaves open specificity optimization in screening.
Observational (n=307)
Yes
Does the in vitro contracture test (IVCT) accurately diagnose malignant hyperthermia susceptibility in patients with previous fulminant MH compared to low-risk subjects?
Absolute Event Rate: 99% vs 93.6%
The in vitro contracture test using the European MH Group protocol demonstrates high sensitivity and satisfactory specificity for diagnosing malignant hyperthermia susceptibility.
Ørding et al. (1997) conducted an observational in Malignant hyperthermia susceptibility (n=307). In vitro contracture test (IVCT) vs. Low-risk subjects (controls) was evaluated on Diagnostic sensitivity and specificity for malignant hyperthermia susceptibility (95% CI Sensitivity: 94.8-100.0; Specificity: 89.2-96.5). The in vitro contracture test for malignant hyperthermia susceptibility showed a diagnostic sensitivity of 99.0% (95% CI 94.8-100.0%) and a specificity of 93.6% (95% CI 89.2-96.5%).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: